BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase II
Alnylam (ALNY)'s Phase II Study Confirms Effectiveness of RNAi Drugs 4/21/2015
Alnylam (ALNY) Reports 12-Month Clinical Data From Phase 2 Open Label Extension (OLE) Study Of Patisiran, An Investigational Rnai Therapeutic For Patients With Familial Amyloidotic Polyneuropathy (FAP) 4/21/2015
FDA Takes Unusual Stance on Genervon's ALS Drug 4/21/2015
BrainStorm Cell Therapeutics Inc. Says Stem Cell Drug Benefits ALS Patients in Mid-Stage Trial 4/21/2015
Patients With Advanced Breast, Lung, Esophageal, And Colorectal Cancers Respond To Immunomedics, Inc. (IMMU)' Novel Antibody-Directed Chemotherapy After Failing Multiple Prior Standard Treatments 4/20/2015
Genticel To Present Further Promising Pharmacology In-Vivo Results Of Its Phase 2 Immunotherapeutic Vaccine Candidate, GTL001 (Procervix), At AACR Annual Meeting 2015 4/20/2015
Anika Therapeutics (ANIK)' Cingal 13-02 Study Meets Primary Endpoint 4/20/2015
Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals, Inc.'s NP001 Potential Efficacy And Safety In ALS 4/20/2015
Pluristem Therapeutics (PSTI)'s Clinical Advisory Board Prepares Phase II Clinical Trials In Critical Limb Ischemia In Europe And Japan 4/20/2015
Atara Biotherapeutics (ATRA)' Collaborating Investigators' Abstract On T-Cell Therapy For EBV Lymphoma To Be Presented At A Clinical Trials Plenary Session At The American Association for Cancer Research Annual Meeting 2015 Is Now Available 4/20/2015
Otonomy, Inc. (OTIC) Completes Enrollment Of OTO-104 Multiple-Dose Safety Study In Meniere's Disease Patients 4/20/2015
EBV-CTL Clinical Trial Data Presented By Atara Biotherapeutics' Collaborating Investigators At A Plenary Session At The AACR Annual Meeting 2015 4/20/2015
Bionomics Limited (BNO.AX) Initiates Phase II Clinical Trial Of BNC210 For Treatment Of Anxiety 4/20/2015
Nymox Pharmaceutical (NYMX) Announces New Prostate Cancer Clinical Trial Results 4/20/2015
DelMar Pharmaceuticals Presents Updated Clinical Data On Phase I/II Study Of VAL-083 In Refractory Glioblastoma Multiforme (GBM) 4/20/2015
Immunocore Limited Announces Positive Clinical Trial Data For Novel First-in-Class Immunotherapy At AACR Annual Meeting 2015 4/20/2015
Can-Fite BioPharma (CFBI) Applies For Orphan Drug Designation In Europe For CF102 In The Treatment Of Liver Cancer 4/20/2015
Opexa Therapeutics (OPXA) Invited To Present Biomarker Data From NMO Patients At The American Academy of Neurology 2015 Annual Meeting 4/20/2015
FDA Grants Fast Track Designation To Eiger Biopharma's Lonafarnib For Hepatitis Delta Virus (HDV) Infection 4/20/2015
Halozyme Therapeutics, Inc. (HALO) Presents New Preclinical Data At AACR Annual Meeting, Announces Clinical Data Presentation At ASCO 4/20/2015
Kamada Ltd. (KMDA) Reports Additional Data From European Phase 2/3 Clinical Study Of Inhaled Alpha-1 Antitrypsin To Treat AAT Deficiency 4/20/2015
Pharmacyclics (PCYC) Release: IMBRUVICA (ibrutinib) Longer-Term Follow-Up Data Demonstrate Durable Responses, Including Complete Responses, In Patients With Chronic Lymphocytic Leukemia (CLL) 4/20/2015
Bristol-Myers Squibb (BMY) Release: First Randomized Study Evaluating Opdivo (Nivolumab)+Yervoy (Ipilimumab) Regimen Demonstrates Superior Efficacy Versus Yervoy Alone In Patients With Previously Untreated Advanced Melanoma 4/20/2015
Discovery Laboratories (DSCO) Ceasing Production of Lead Drug Surfaxin, Chops 50% Employees 4/17/2015
Athersys (ATHX) Craters as Stem Cell Therapy Fails Phase II Stroke Study 4/17/2015
Targacept (TRGT) Winces As Last Remaining Drug Candidate Flops in Phase II Trial 4/17/2015
RXi Pharmaceuticals (RXII) Receives Orphan Drug Designation For Samcyprone From The U.S. FDA For The Treatment Of Malignant Melanoma Stage IIb to IV 4/17/2015
Bionomics Limited (BNO.AX) Showcases Oncology Drug Development Programs At 2015 American Association for Cancer Research Annual Meeting 4/17/2015
Athersys (ATHX) Announces Results From Phase 2 Study Of Multistem Cell Therapy For Treatment Of Ischemic Stroke 4/17/2015
Anika Therapeutics (ANIK) Reports On Cingal 13-01 Study Clinical Trial Top Line Data And Announces The Completion Of Cingal 13-02 Study’s Patient Enrollment 4/17/2015
Burzynski Research Institute Announces Publication Of Phase II Results In Patients With Non-Diffuse Intrinsic Pontine Glioma 4/17/2015
Ariad (ARIA) Presents Updated Clinical Data On Brigatinib In Patients With ALK+ Non-Small Cell Lung Cancer 4/17/2015
Aldeyra Therapeutics (ALDX) Announces First Patient Enrolled In Noninfectious Anterior Uveitis Phase II Clinical Trial 4/16/2015
Receptos (RCPT) Reports Positive Results For The Maintenance Period Of The Phase 2 TOUCHSTONE Trial Of Ozanimod In Ulcerative Colitis 4/16/2015
StemCells (STEM) Completes Enrollment Of First Cohort In Phase II Pathway Study For Cervical Spinal Cord Injury 4/16/2015
EMD Serono Highlights Scientific Commitment To MS With Data Presented At The American Academy of Neurology Annual Meeting 4/16/2015
FDA Grants Fast Track Designation For MediciNova, Inc.'s MN-001 (Tipelukast) For The Treatment Of NASH With Fibrosis 4/16/2015
Celgene (CELG) Release: Phase II Data For Apremilast In Behçet’s Disease Published In The New England Journal of Medicine 4/16/2015
DelMar Pharmaceuticals Adds Fourth Clinical Trial Site In Phase I/II Multicenter Study Of VAL-083 For Recurrent Malignant Glioma 4/16/2015
Biogen (BIIB) Shoots Up Following Positive Eye Drug RENEW Trial Data 4/15/2015
Replicel Life Sciences Receives Approval To Conduct Clinical Trial For Patients With Chronic Achilles Tendinosis 4/15/2015
Biogen (BIIB) Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair 4/15/2015
Celsion Corporation (CLSN) Announces Positive Interim Data From Its Phase 2 DIGNITY Study In Breast Cancer 4/15/2015
Biothera Immunotherapy Combination Results In Tumor Reduction During Maintenance Phase Of Non-Small Cell Lung Cancer Study 4/15/2015
Biogen (BIIB) Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair 4/15/2015
Pharmalink AB Phase II Trial Of Nefecon Halted Early 4/14/2015
Bayer HealthCare (BAY) Devises Phase III Plans for Top Prospect 4/14/2015
Puma Biotechnology (PBYI) Expands Cohort In Phase II Trial Of PB272 In HER2 Mutation Positive Cancer Patients 4/14/2015
Clear Guide Medical Receives $1.5 Million NIH Funding To Make Ultrasound-Guided Procedures Easier 4/14/2015
Prolong Pharmaceuticals Presents Data On Unique "Un-Sickling" In Vitro Activity Observed In Sickle Cell Investigational Drug SANGUINATE 4/14/2015
GeoVax Labs Inc. (GOVX.OB) To Seek Dual Pathway For Advancing Its HIV Preventive Vaccine 4/14/2015
Mechanism Of Action Of ABIVAX's First-in-class Anti-HIV Drug Published Today In Peer-Reviewed Journal Retrovirology 4/13/2015
Versartis, Inc. (VSAR) Initiates Phase 2/3 Trial Of VRS-317 In Japan For Children With Growth Hormone Deficiency 4/13/2015
Rheonix, Inc. Receives $1.5 Million SBIR Phase II Grant From The National Institute Of Dental And Craniofacial Research Of The NIH To Complete Development Of A Rapid Point-Of-Care Test For HIV/AIDS 4/13/2015
ARCA biopharma Receives FDA Fast Track Designation For Gencaro Atrial Fibrillation Development In A Genetically Targeted Heart Failure Population 4/13/2015
Arrowhead Research Corporation (ARWR) Cleared To Proceed With Multiple Dose Phase 2b Study Of ARC-520 4/13/2015
Merck & Co. (MRK) Breathes a Sigh of Relief as the FDA Calls Hepatitis C Drugs a Breakthrough 4/10/2015
Will AbbVie (ABBV)'s HCV Candidates Threaten Gilead (GILD)? 4/10/2015
Admedus Herpes Phase II – First Dosing To Commence 4/10/2015
EXCLUSIVE: Collaboration to Find Pancreatic Cancer Biomarker Could See Lead Candidate by 2018, Says Berg CTO 4/9/2015
Recro Pharma (REPH) Announces Update On On-Going Phase II Clinical Trial Of Dex-IN For Treatment Of Acute Pain On Day 1 Following Surgery 4/9/2015
Dermira Doses First Patient In DRM01 Phase IIb Acne Trial 4/9/2015
BioBlast Pharma (ORPN) Announces Granting Of Fast Track Designation By The FDA For Cabaletta In Oculopharyngeal Muscular Dystrophy (OPMD) 4/9/2015
Shire (SHPGY) Reports Topline Results From First Of Three Placebo-Controlled Phase 2 Studies Of SHP625 (LUM001) In Children With Alagille Syndrome 4/9/2015
Pharmacyclics (PCYC) Release: New Longer-Term IMBRUVICA (ibrutinib) Data Show High Response Rates In Patients With Waldenstrom's Macroglobulinemia 4/9/2015
Onxeo Release: Belinostat Phase I/II Results In Soft Tissue Sarcoma To Be Presented At The 2015 Annual ASCO Meeting 4/9/2015
Clovis Oncology (CLVS) Shares Leap as FDA Deems Ovarian Cancer Drug a Breakthrough, Company Preps for ARIEL3 4/8/2015
Rhythm Initiates Phase 2b Clinical Trial Of Relamorelin For Diabetic Gastroparesis 4/8/2015
Regulus Therapeutics, Inc. (RGLS) Release: RG-125 (AZD4076), A microRNA Therapeutic Targeting Microrna-103/107 For The Treatment Of NASH In Patients With Type 2 Diabetes/Pre-Diabetes, Selected As Clinical Candidate By Astrazeneca 4/8/2015
Capricor Therapeutics, Inc. Completes Enrollment Of Initial Phase Of DYNAMIC Clinical Trial Of Cardiosphere-Derived Cell Therapy For Treatment Of Advanced Heart Failure 4/8/2015
BioSpecifics Technologies Corporation (BSTC) To Present At The 14th Annual Needham Healthcare Conference 4/8/2015
Athersys, Inc. (ATHX) Phase 2 Ischemic Stroke Clinical Trial Results To Be Presented At European Stroke Conference 4/8/2015
Prolong Pharmaceuticals' Flagship Product SANGUINATE Granted Orphan Drug Designation By The FDA 4/8/2015
DiscoveryBioMed Is Awarded A New Phase II SBIR Grant Award To Develop New Medicines To Fight The Diabetes And Obesity Epidemic In The U.S. And Globally 4/8/2015
Benitec, Inc. (BLT.AX) Provides Update On TT-034 Trial 4/7/2015
Delcath Systems, Inc. (DCTH) Adds New U.S. Center To Global Phase 2 Hepatocellular Carcinoma Program 4/7/2015
YPrime Awarded Global Phase II Oncology Clinical Trial Which Will Utilize Proprietary eClinical Supply Forecasting Tool Combined With IRT 4/7/2015
Celldex (CLDX)' Phase 2 EMERGE Study Of Glembatumumab Vedotin In Metastatic Breast Cancer Published In Journal Of Clinical Oncology 4/7/2015
Progenics Pharmaceuticals, Inc. (PGNX) Announces The Initiation Of Fuji's Phase 2 Trial For 1404 In Japan 4/7/2015
Clovis Oncology (CLVS) Receives Breakthrough Therapy Designation For Rucaparib For Monotherapy Treatment Of Advanced Ovarian Cancer In Patients With BRCA-Mutated Tumors (Inclusive Of Both Germline And Somatic BRCA Mutations) 4/7/2015
Celtaxsys, Inc. Has Regulatory Clearance To Begin Phase 2 Trial Of Oral CTX-4430 Anti-Inflammatory Therapy For Moderate To Severe Acne Vulgaris - Recruitment Of Patients To Commence Immediately 4/7/2015
Alkermes (ALKS) Announces Positive Topline Results From Complete Six-Month Phase 2 Clinical Trial Of ALKS 3831 In Schizophrenia 4/6/2015
Neurotrope Selects Worldwide Clinical Trials To Commence Services For Phase 2B Trial Of Bryostatin For The Treatment Of Alzheimer's Disease 4/6/2015
Advaxis, Inc. And RTOG Foundation To Collaborate On Pivotal Phase 2/3 Clinical Trial Of ADXS-HPV In Anal Cancer 4/6/2015
AstraZeneca PLC (AZN)'s Failed Cancer Drug Finds New Life in Alzheimer’s Treatment 4/3/2015
Flexion (FLXN) CEO Discusses Pipeline and Jobs 4/3/2015
Replicor Announces Completion Of Enrollment In Phase II Trial 4/3/2015
Clementia Advances Phase 2 Clinical Trial Of Palovarotene In Fibrodysplasia Ossificans Progressiva Based On Recommendations From Data Monitoring Committee (DMC) 4/2/2015
Public Health Agency of Canada Release: Clinical Trials Prove Canada's VSV-EBOV Ebola Vaccine Safe And Effective 4/2/2015
Astellas Pharma Inc. (ALPMY) Release: Enzalutamide Demonstrates Statistically Significant Improvement In Progression Free Survival Compared With Bicalutamide In Strive Trial 4/2/2015
Ocera Therapeutics, Inc. (OCRX) Completes Interim Analysis Of OCR-002 In Phase 2b STOP-HE Study For The Treatment Of Acute Hepatic Encephalopathy 4/2/2015
Teva (TEVA) And Xenon Pharmaceuticals Inc. Announce Enrollment Of First Patient In A Phase 2b Study Evaluating TV-45070 For Postherpetic Neuralgia (PHN) 4/2/2015
Perosphere Inc. Receives FDA Fast Track Designation For Investigational Anticoagulant Reversal Agent PER977 4/2/2015
GeoVax Labs Inc. (GOVX.OB) Provides Update On Its HIV Vaccine Program 4/2/2015
SAGE Therapeutics Announces Positive End-Of-Phase 2 Meeting With FDA And Planned Initiation Of SAGE-547 Global Phase 3 Trial In Mid-2015 4/2/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX)'s RGN-259 Meets Key Efficacy Objectives In Phase II Clinical Trial In Patients With Severe Dry Eye Reported In Current Issue Of Cornea 4/1/2015
Sigma-Tau Pharmaceuticals Receives Orphan Drug Designation For STP-206 For Prevention Of Necrotizing Enterocolitis 4/1/2015
ESSA Pharma Announces Filing Of Investigational New Drug Application For EPI-506 4/1/2015
NeuroDerm Ltd. (NDRM) To Announce Updated Topline Results Of Phase II Study Of Continuous, Subcutaneously-Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease At The 67th Annual Meeting Of The American Academy of Neurology 4/1/2015
Sigma-Tau Pharmaceuticals Receives Orphan Drug Designation For STP-206 For Prevention Of Necrotizing Enterocolitis 4/1/2015
Servier Initiates Phase 2 Study Of Gevokizumab In Patients With Diabetic Nephropathy 4/1/2015
NIH Funds Study Of Fully Personalized Immunotherapy AGS-004 Combined With A Latency Reversing Therapy For The Treatment Of HIV 4/1/2015
Pharmacyclics (PCYC) Release: Solid Tumor Study Investigating Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Commences In Patients With Relapsed/Refractory Non-Small Cell Lung, Breast And Pancreatic Cancers 4/1/2015
Hutchison Medipharma's Cancer Drug Meets Endpoint In Phase II Trial 4/1/2015
Anergis Announces Completion Of Treatment In AllerT Phase II Dose-Ranging Trial 4/1/2015
Burzynski Research Institute Announces Publication Of Phase II Results In Adults With Newly-Diagnosed Anaplastic Astrocytoma 4/1/2015
Kala Pharmaceuticals KPI-121 Meets Primary Sign Endpoint In Phase II For Dry Eye Disease 4/1/2015
RedHill Biopharma Ltd. (RDHL) Acquires Phase II First-in-Class Oral Small Molecule SK2 Inhibitor From Apogee Biotech 3/31/2015
Capricor Therapeutics, Inc. Completes Enrollment Of Phase II Clinical Trial For Cenderitide To Treat Heart Failure 3/31/2015
BioTie Therapies Corp. Announces Start Of Patient Enrolment Into Phase IIa Clinical Study With BTT1023 In Primary Sclerosing Cholangitis 3/31/2015
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Promising Bavituximab Phase I Data Published In The Peer-Reviewed Journal Cancer Medicine In Advanced Metastatic Breast Cancer 3/31/2015
Emisphere Technologies, Inc. (EMIS) Reports Fourth Quarter And Full Year 2014 Financial Results 3/31/2015
Intra-Cellular Therapies, Inc. Presents The ITI-007 Clinical Development Program At The 15th International Congress On Schizophrenia Research 3/31/2015
Ocata Therapeutics Successfully Completes Dosing In Phase 1/2 RPE Studies 3/31/2015
Can-Fite BioPharma (CFBI) PhII/III: CF101 Did Not Achieve Primary Endpoint 3/30/2015
Ohr Pharma (OHRP)'s OHR-102 Fails in Phase II, Shares Plunge 3/30/2015
GENFIT (ALGFT)'s GFT505 Misses Target in Phase IIB But Hopes to Proceed to Phase III 3/30/2015
Can-Fite BioPharma (CFBI) Files 2014 Annual Report On Form 20-F 3/30/2015
Synthetic Biologics, Inc. (SYN) Initiates Phase 2a Clinical Trial Of SYN-004 To Protect The Microbiome And Prevent C. Difficile 3/30/2015
Innate Pharma (IPH.PA ) : DSMB Recommends Continuation Of Effikir Trial With Two Arms 3/30/2015
CASI Pharmaceuticals  (CASI) Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3/30/2015
BioMarin (BMRN) Announces One Oral And 7 Poster Presentations At The 2015 American College Of Medical Genetics And Genomics Annual Clinical Genetics Meeting 3/30/2015
Conatus Pharma Shares Soar On Successful Emricasan Phase II Results 3/27/2015
Ohr Pharma (OHRP) Announces Final Topline Data From OHR-102 Phase II IMPACT Study In Wet-AMD 3/27/2015
Proteon Therapeutics, Inc. (PRTO) Announces Positive Long-Term Results From Phase 2 Study Of Investigational New Drug Vonapanitase In Chronic Kidney Disease Patients Undergoing Surgical Creation Of An Arteriovenous Fistula For Hemodialysis 3/27/2015
NIH Release: Ebola Test Vaccines Appear Safe In Phase 2 Liberian Clinical Trial 3/27/2015
Burzynski Research Institute Announces Publication Of Phase 2 Clinical Study In Metastatic Colon Adenocarcinoma Of The Liver 3/27/2015
PharmaCyte Biotech (NVLX) On Track to Commence Clinical Trials 3/27/2015
GENFIT (ALGFT) Announces Topline Results From The Golden-505 Trial In Nash 3/26/2015
Otonomy, Inc. (OTIC) Initiates Phase 2 Clinical Trial for AuriPro(TM) In Label Expansion Indication 3/26/2015
Galena Biopharma  (GALE) Expands Patient Population In NeuVax(TM) (nelipepimut-S) And Trastuzumab Phase 2b Combination Clinical Trial In HER2 1+/2+ Patients 3/26/2015
Conatus Pharmaceuticals Inc. Announces Successful Top-Line Results From NAFLD/NASH Clinical Trial Of Emricasan 3/26/2015
Aldeyra Therapeutics (ALDX) Opens Enrollment In Noninfectious Anterior Uveitis Phase II Clinical Trial 3/26/2015
Apceth GmbH Initiates Phase II Clinical Trial For Pioneering Engineered Cell Therapy To Treat Gastrointestinal Cancer 3/26/2015
Amarantus BioSciences, Inc. Opens Investigational New Drug (IND) Application With The U.S. FDA Allowing The Start Of A Phase 2b Program Of Eltoprazine In Parkinson's Disease Levodopa-Induced Dyskinesia 3/26/2015
MorphoSys AG And Celgene (CELG) Mutually Agree To End MOR202 Collaboration 3/26/2015
Dermira Reports Fourth Quarter And Full Year 2014 Financial Results And Provides Corporate Update 3/26/2015
Cardio3 BioSciences Reports 2014 Financial And Operating Results 3/26/2015
Neothetics Reports Fourth Quarter and Full Year 2014 Financial Results 3/26/2015
CASI Pharmaceuticals  (CASI) Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 3/25/2015
Agios Pharmaceuticals (AGIO) Announces Orphan Drug Designation Of AG-348 For Treatment Of Pyruvate Kinase Deficiency 3/25/2015
Lpath, Inc. (LPTN) Reports Results For ASONEP Phase 2a Study In Renal Cell Carcinoma 3/25/2015
Signum Dermalogix Out-Licenses SIG990 To Dermata Therapeutics For Topical Treatment of Rosacea 3/25/2015
Regulus Therapeutics, Inc. (RGLS) Receives Orphan Medicinal Product Designation From The European Commission (EC) For RG-012, A Microrna Therapeutic In Development For The Treatment Of Alport Syndrome 3/25/2015
VBL Therapeutics (VBLX) Reports Interim Topline Results From Phase 2 Clinical Trial Of VB-111 In Recurrent Glioblastoma (Rgbm) 3/25/2015
Cellular Biomedicine Group (CBMG) Announces Interim Results From Phase IIb Clinical Trial For Knee Osteoarthritis Stem Cell Rejoin Therapy 3/25/2015
Marinus Pharmaceuticals (MRNS)' Ganaxolone Receives FDA Orphan Drug Designation In PCDH19 Female Epilepsy 3/25/2015
TRANSGENE (ENX:TNG) Reports 2014 Financial Results And Outlines Promising Clinical Pipeline 3/25/2015
Mologen AG (MOLGF.PK): Start Of Pivotal Study For Cancer Immunotherapy MGN1703 Influences 2014 Annual Result 3/25/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Status From The European Medicines Agency For Ovarian Cancer 3/25/2015
Why Investors Shouldn't Freak Out Over Vertex (VRTX)'s Latest Trial Results 3/24/2015
Aldeyra Therapeutics (ALDX) Announces First Patient Enrolled In Sjogren-Larsson Syndrome Phase II Clinical Trial 3/24/2015
NGM Announces Positive Phase II Clinical Data In Primary Biliary Cirrhosis Patients For NGM282, A First-In-Class Investigational Medicine 3/24/2015
Pluristem Therapeutics (PSTI) Announces Key Strategic Objectives For Development Of PLX-R18 In Hematopoietic Indications 3/24/2015
MediGene AG (MDGEF.PK) Starts Phase I/II Study With DC Vaccine To Treat Acute Myeloid Leukaemia (AML) 3/24/2015
Astellas Pharma Inc. (ALPMY) And Medivation, Inc. (MDVN) Announce New Enzalutamide Data Presented During Plenary Presentations At The 2015 European Association Of Urology Congress 3/24/2015
Soligenix (SNGX) Announces Recent Accomplishments And Year-End 2014 Financial Results 3/24/2015
GenVec Inc. (GNVC) Reports Fourth Quarter And 2014 Year-End Financial Results 3/24/2015
Mast Therapeutics (MSTX) Reports Fourth Quarter And Full Year 2014 Financial Results 3/24/2015
Eli Lilly (LLY),Novartis AG (NVS)-Backed Startup, Aeglea, Nabs $44 Million 3/23/2015
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Announces Top-Line Data From Randomized Phase II Clinical Study Of Pracinostat In Front-Line Myelodysplastic Syndrome 3/23/2015
Can-Fite BioPharma (CFBI) Signs Multi-Million Dollar Distribution Agreement For CF101 In Canada With Cipher Pharmaceuticals (DND.TO) 3/23/2015
GenVec Inc. (GNVC) And TheraBiologics Form Collaboration To Develop Neural Stem Cell Mediated Cancer Therapies 3/23/2015
Cipher Pharmaceuticals (DND.TO) Acquires Canadian Rights To Novel Treatment For Psoriasis And Rheumatoid Arthritis 3/23/2015
Mast Therapeutics (MSTX) To Develop Vepoloxamer (MST-188) In Chronic Heart Failure 3/23/2015
Anavex (AVXL) Presents Positive Results For Both ANAVEX 2-73 And ANAVEX 3-71 In Alzheimer's Models At 2015 AD/PD Conference 3/23/2015
OncoGenex Pharmaceuticals Inc. (OGXI) To Report Financial Results For Fourth Quarter And Year End 2014 On March 26, 2015 3/23/2015
Lpath, Inc. (LPTN) To Hold Investor Update Conference Call 3/23/2015
Clinical Data For Dermira's DRM01 Acne Program Presented At Dermatology Meeting 3/23/2015
Teva (TEVA)'s TEV-48125 Meets Primary And Secondary Endpoints In Episodic Migraine Study, Demonstrating Treatment Concept After A Single Dose 3/23/2015
Vertex (VRTX) Announces Data From 12-Week Phase 2 Safety Study Of VX-661 In Combination With Ivacaftor In People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation 3/23/2015
Bone Therapeutics Treats First Patients In ALLOB Phase IIA Spinal Fusion Trial 3/23/2015
Intercept Pharmaceuticals (ICPT) Announces New Data Analyses From FLINT Trial Of Obeticholic Acid In NASH 3/20/2015
Dilaforette Receives Orphan Drug Designation In The U.S. For Sevuparin In Sickle-Cell Disease 3/20/2015
Cerulean Pharma Inc. (CERU) Announces Phase 1b/2 Trial Of CRLX101 In Combination With Avastin In Relapsed Renal Cell Carcinoma Meets Primary Endpoint 3/20/2015
Boehringer Ingelheim Pharmaceuticals, Inc.'s Investigational Biologic Cleared Skin Better Than Ustekinumab In Head-To-Head Phase II Psoriasis Study 3/20/2015
Dignity Sciences Presents Late-Breaking News Abstract On DS107 At American Academy of Dermatology Annual Meeting 3/20/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Establishes Manufacturing Agreement With Pharmacell B.V. For European Production Of ICT-107 For Phase 3 Registration Trial 3/19/2015
PTC Therapeutics (PTCT) And University of Pennsylvania Collaborate On Orphan Disease Research 3/19/2015
Phase II Data For Celgene (CELG)’s Investigational Oral GED-0301 For Patients With Active Crohn’s Disease Published In New England Journal Of Medicine 3/19/2015
BioInvent (BOVNF) Confirms Clinical Strategy For BI-505 And Plans To Conduct Phase IIa Trial In Multiple Myeloma Post-Stem Cell Transplant Patients In The U.S. 3/19/2015
Hemostemix Expands Clinical Trial For Critical Limb Ischemia (CLI) To Four Sites In South Africa, Treats First South African Participant 3/19/2015
Threshold Pharmaceuticals, Inc. (THLD) To Present Data Supporting Planned Phase 2 Trials Of TH-4000, A Hypoxia-Activated, Irreversible EGFR Tyrosine Kinase Inhibitor 3/19/2015
Creabilis' CT327 Phase 2b Data Published In Acta Dermato-Venereologica, Strengthens Scientific Advisory Board 3/19/2015
Eli Lilly (LLY), Hanmi Pharma Forge $690 Million Autoimmune Pact 3/19/2015
Selten Pharma, Inc. Receives Orphan Drug Designation From U.S. FDA For The Treatment Of Pulmonary Arterial Hypertension 3/18/2015
BioPharmX Corporation Completes Pre-IND Meeting With U.S. FDA To Review Its Topical Acne Solution 3/18/2015
Can-Fite BioPharma (CFBI) Completes Development Of Commercial Biomarker Test To Predict Patients' Response To Company Drugs 3/18/2015
Ascletis, Inc. Reports Strong Phase II Data For Hepatitis C Drug 3/18/2015
Novan Therapeutics Achieves Target Enrollment For Phase 2 Acne Study 3/18/2015
Allena Pharmaceuticals, Inc. Announces Positive Phase IIa Data Of ALLN-177 For The Treatment Of Hyperoxaluria 3/18/2015
La Jolla Pharmaceutical Company (LJPC) Announces Initiation Of Phase 2b Clinical Trial Of GCS-100 In Advanced Chronic Kidney Disease 3/18/2015
Imperial Innovations' Cell Medica Granted Orphan Drug Designation For Novel Cellular Therapy And Treats First Lymphoma Patient In CITADEL Phase II Trial 3/18/2015
Biogen Idec (BIIB) Will Be Hiring in R&D After Around 20 Employees Leave Following Review 3/17/2015
Here's Why Investors are Already Anticipating Vertex (VRTX) Trial Data Coming This Month 3/17/2015
Kindred Bio (KIN) Announces Positive Results Of Pilot Field Study Of KIND-012 For The Control Of Fever In Horses 3/17/2015
Ablynx (ABLYF) Initiates The First Of Two Phase IIb Ra Studies With Its Anti-Il-6R Nanobody, Partnered With AbbVie (ABBV) 3/17/2015
Cellerant Therapeutics, Inc. Announces Dosing Of First Patient In Randomized Phase 2 Clinical Trial Of CLT-008 In Acute Myeloid Leukemia Patients 3/17/2015
Aldeyra Therapeutics (ALDX) Opens Enrollment In Sjogren-Larsson Syndrome Clinical Trial And Finalizes Noninfectious Anterior Uveitis Clinical Trial Protocol 3/17/2015
Ocata Therapeutics Receives Regulatory Guidance From European Medicines Agency 3/17/2015